How would you plan to give Carboplatin, Taxol and Trastuzumab postoperatively for a patient with serous endometrial cancer, HER 2 positive, that received 6 cycles of NACT with Carboplatin and taxol?

Community
Company
News
Contact Us
Sign in

Topics: Gynecologic Cancers • Endometrial Cancer • Medical Oncology

Would you plan it differently knowing the patient has stage IV disease?

Related Questions

What is your preferred first line systemic treatment for recurrent, metastatic, low grade, ER/PR+ pMMR endometrioid endometrial carcinoma?

When do you expect the 2023 FIGO staging for endometrial cancer to become adopted clinically in the US?

Do you screen for immune-related adrenal insufficiency for patients on immune checkpoint inhibitors?

How would you manage a POLE mutated, p53 abnormal IA myoinvasive carcinosarcoma of the endometrium with no LVSI?

Would you consider offering immunotherapy +/- olaparib to a patient with early-stage endometrial carcinoma for whom you are recommending adjuvant chemotherapy based on improved outcomes seen in RUBY/DUO-E/NRG-GY018?

What do you view as the future role for the combination of durvalumab + olaparib + chemotherapy in the management of patients with advanced/recurrent endometrial cancer following the DUO-E trial results?

For patients with advanced endometrial cancer, are the improved outcomes in PFS from DUO-E/RUBY/NRG-GY018 sufficient to move immunotherapy to the frontline for all presuming FDA approval?

What are your top takeaways in Gynecologic Cancers from ASCO 2023?

Based on the data from GY018 and RUBY, do you offer immunotherapy in addition to carboplatin/paclitaxel first line to all patients with advanced endometrial cancer who qualify or only to those whose tumors are MMR protein deficient?

What are your top takeaways from SGO 2024?